Pfizer Inc. and Valneva SE announced that Pfizer, as the study sponsor, has discontinued approximately half of the total recruited participants in the U.S. enrolled in the Vaccine Against Lyme for Outdoor Recreationists (VALOR) Phase 3 clinical trial investigating the efficacy, safety, and immunogenicity of Lyme disease vaccine candidate, VLA15. These study participants are being discontinued following violations of Good Clinical Practice (GCP) at certain clinical trial sites run by a third-part...